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17𝛽-Hydroxysteroid dehydrogenase type 1 (17𝛽-HSD1) catalyzes the conversion of estrone to the potent estrogen estradiol. 17𝛽-
HSD1 is highly expressed in breast and ovary tissues and represents a prognostic marker for the tumor progression and survival
of patients with breast cancer and other estrogen-dependent tumors. Therefore, the enzyme is considered a promising drug target
against estrogen-dependent cancers. For the development of novel inhibitors, an improved understanding of the structure-function
relationships is essential. In the present study, we examined the role of a cysteine residue, Cys10, in the Rossmann-fold NADPH
binding region, for 17𝛽-HSD1 function and tested the sensitivity towards sulfhydryl modifying chemicals. 3D structure modeling
revealed important interactions of Cys10 with residues involved in the stabilization of amino acids of the NADPH binding pocket.
Analysis of enzyme activity revealed that 17𝛽-HSD1was irreversibly inhibited by the sulfhydrylmodifying agents N-ethylmaleimide
(NEM) and dithiocarbamates. Preincubation with increasing concentrations of NADPH protected 17𝛽-HSD1 from inhibition by
these chemicals. Cys10Ser mutant 17𝛽-HSD1 was partially protected from inhibition by NEM and dithiocarbamates, emphasizing
the importance of Cys10 in the cofactor binding region. Substitution of Cys10 with serine resulted in a decreased protein half-life,
without significantly altering kinetic properties. Despite the fact that Cys10 on 17𝛽-HSD1 seems to have limited potential as a target
for new enzyme inhibitors, the present study provides new insight into the structure-function relationships of this enzyme.
1. Introduction
17𝛽-Hydroxysteroid dehydrogenase (17𝛽-HSD) enzymes are
involved in the interconversion of inactive and active
sex-steroid hormones, thereby playing an essential role
in the intracrine regulation of estrogen-, androgen-, and
progesterone-dependent physiological functions [1]. 17𝛽-
HSD1 is responsible for the conversion of estrone to estradiol,
the most potent natural estrogen. The highest expression of
this enzyme is found in breast and ovarian tissue. Impor-
tantly, 17𝛽-HSD1 expression showed a negative correlation
with breast cancer progression and was identified as an
independent prognostic marker for the disease-free and
overall survival of patients with breast cancer [2, 3]. Elevated
expression of 17𝛽-HSD1 was observed in endometrial cancer
[4] and nonsmall cell lung cancer [5]. Furthermore, the
expression ratio of 17𝛽-HSD1 and 17𝛽-HSD2 was found to be
a predictor of the response to tamoxifen in postmenopausal
breast cancer patients [6].
The administration of specific 17𝛽-HSD1 inhibitors led
to significantly decreased tumor growth in breast cancer cell
xenograft tumor mouse models [7, 8] and reversed estrogen-
dependent endometrial hyperplasia in transgenic mice [9],
indicating that this enzyme is a promising drug target
against estrogen-dependent diseases such as endometriosis
and endometrial cancer as well as breast and ovarian tumors.
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Several classes of chemicals inhibiting 17𝛽-HSD1 were tested
in vitro, including steroid-like molecules, nonsteroidal com-
pounds, and chimeric molecules, acting on both the active
center and the cofactor binding site of the enzyme [8, 10–
16]. However, only a limited number of inhibitors have been
tested in vivo so far and further research is needed. In order to
develop potent and selective 17𝛽-HSD1 inhibitors, a profound
understanding of the structure-function relationships of the
enzyme is essential.
17𝛽-HSD1 belongs to the short-chain dehydrogenase/
reductase (SDR) family and contains the conserved Ross-
mann-fold for nucleotide binding, the catalytic triad with
residues Ser142, Tyr155, and Lys159 [17] and a dimerization
region. Lys149 is a critical residue for the discrimination
between C-18 and C-19 steroid substrates [18].
Targeting of functionally essential cysteine residues in
proteins is suggested as a promising approach for the design
of new types of pharmaceutical agents [19]. 17𝛽-HSD1 con-
tains six cysteines. In a previous study, we demonstrated
that the structurally related enzyme 11𝛽-hydroxysteroid dehy-
drogenase type 2 (11𝛽-HSD2) contains a cysteine residue at
position 90, analogous to Cys10 on 17𝛽-HSD1 [20]. Mutation
of Cys90 on 11𝛽-HSD2 led to almost complete inactivation
of the enzyme. Therefore, we hypothesized that Cys10 on
17𝛽-HSD1 may represent a target site for novel inhibitors.
In the present study, we applied 3D structure modeling and
enzyme activity measurements to investigate the biochemical
properties of Cys10Ser mutant 17𝛽-HSD1 and to compare its
sensitivity towards sulfhydryl modifying agents with that of
wild-type 17𝛽-HSD1.
2. Materials and Methods
Cell culture media were purchased from Invitrogen (Carls-
bad, CA) and [2,4,6,7-3H]-estrone from Amersham Pharma-
cia (Piscataway, NJ, USA). All other chemicals were from
Fluka AG (Buchs, Switzerland) and of the highest grade
available.
2.1. Construction of Expression Plasmids and Site-Directed
Mutagenesis. In order to facilitate detection, an octahistidine
tag was added to the C-terminus of human 17𝛽-HSD1 by
PCR amplification using oligonucleotide primers containing
the tag-coding sequence (forward primer 5󸀠-TAAACC-
CTGAGGAGGTGGCGGAGGTCTTC-3󸀠, reverse primer
5󸀠-TGCTCTAGAAGCTTAATGATGATGATGATGATG-
ATGATGCTGCGGGGCGGCCGGAGGATCG-3󸀠). The
activity of the tagged 17𝛽-HSD1 was indistinguishable from
that of the untagged enzyme. The substitution of Cys10
to serine was introduced into the C-terminal histidine-
tagged 17𝛽-HSD1 cDNA in Bluescript vector by site-directed
mutagenesis using the forward primer 5󸀠-TCATCACCG-
GCTCTTCCTCG-3󸀠 and the reverse primer 5󸀠-GAGGAA-
GAGCCGGTGATGAG-3󸀠 according to the Quick Change
mutagenesis kit (Stratagene, Amsterdam, The Netherlands),
followed by subsequent recloning into pcDNA3.1 expression
plasmid.
2.2. Cell Culture, Transfection, and Western Blotting. HEK-
293 cells were grown to 60–70% confluence in Dulbecco’s
Modified Eagles Medium (DMEM) supplemented with 10%
fetal bovine serum, 4.5 g/L glucose, 50 units/mL peni-
cillin/streptomycin, and 2 mM glutamine, followed by trans-
fection using the calcium phosphate precipitation method.
The transfection efficiency was 32 ± 3%. To examine the
expression levels of the overexpressed proteins, we performed
SDS-PAGE (30 𝜇g of total cellular proteins loaded per lane)
followed by immunoblotting and detection of the histidine-
tagged proteins using tetra-His antibody (Qiagen GmbH,
Hilden, Germany; Cat. No. 11561526). As a loading control
𝛽-Actin was visualized using an anti-𝛽-actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA; Cat. No. B1204).
2.3. 17𝛽-HSD1 Activity Measurements. To determine 17𝛽-
HSD1 activity, HEK-293 cells were transfected by the calcium
phosphate precipitation method. Cells were harvested 48 h
after transfection, washed twice with phosphate-buffered
saline (PBS), and centrifuged for 4min at 150×g. Super-
natants were removed and the cell pellets were quick-frozen
in a dry ice-ethanol bath and stored at −80∘C. The reductase
activity of 17𝛽-HSD1 was measured by incubation of cell
lysates for 10min at 37∘C in the presence of 200 nM radi-
olabeled estrone and 400𝜇M NADPH in a reaction buffer
containing 20% glycerol, 1mMEDTA, and 50mMpotassium
phosphate, pH 7.4. Inhibitors were diluted from stock solu-
tions in dimethylsulfoxide (DMSO) and immediately used in
the assays.TheDMSO concentration did not exceed 0.1% and
had no effect on the enzyme activities.
For the enzyme activity assay in intact cells,HEK-293 cells
were grown in 10 cm culture dishes, transfectedwith plasmids
for histidine-tagged wild-type 17𝛽-HSD1 or Cys10Ser mutant,
detached 24 h after transfection and distributed in 96-well
plates at a density of 10,000 cells per well. After 16 h,
cells were incubated in serum- and steroid-free medium,
and the conversion of radiolabeled estrone to estradiol was
determined upon incubation for 30min at 37∘C in a total
volume of 50 𝜇L containing 200 nM estrone. The reaction
was stopped by adding methanol containing 2mM unlabeled
estrone and estradiol, followed by separation of steroids by
TLC and scintillation counting.
For determination of enzyme kinetics, estrone concentra-
tions ranging from 10 to 800 nMwere used.Data (mean± SD)
were obtained from three independent experiments and were
calculated using the Data Analysis Toolbox (Elsevier MDL,
Allschwil, Switzerland).
2.4. Analysis of the Protein Stability of Wild-Type 17𝛽-HSD1
and Mutant Cys10Ser. The stability of wild-type and mutant
17𝛽-HSD1 protein was analyzed basically as described previ-
ously [21]. Briefly, to investigate the protein half-life of wild-
type 17𝛽-HSD1 and mutant Cys10Ser, HEK-293 cells grown
in six-well plates were transfected with plasmids for mutant
and wild-type enzyme, washed once with PBS 24 h after
transfection, and incubated with fresh medium containing
50𝜇g/mL cycloheximide. At 0, 12, 24, and 48 h, aliquots of
cells were harvested, followed by immunodetection using
International Journal of Cell Biology 3
𝛽-strand A Turn 𝛼-helix B 𝛽-strand B
-46
-46
-46
-46
-46
-48
-98
-125
-125
-72
-72
-71
-72
-68
h17𝛽-HSD1
bt17𝛽-HSD1
rn17𝛽-HSD1
mm17𝛽-HSD1
dr17𝛽-HSD1
hRDH8
hBDH
h17𝛽-HSD2
h11𝛽-HSD2
h3𝛼-HSD
h17𝛽-HSD6
hRDH1
hRDH16
hSDR-O ∗↑
1-
1-
1-
1-
1-
3-
53-
80-
80-
27-
27-
26-
27-
23-
∗ ∗
(a)
(b)
Figure 1: Sequence alignment of the cofactor binding domain of 17𝛽-HSD1. Peptide sequences of human (h), bovine (bt), rat (rn), mouse
(mm), and zebrafish (Danio rerio, dr) 17𝛽-HSD1 (SDR28C1) are shown in the upper panel and those of the related human SDR enzymes
all-trans retinol dehydrogenase RDH8 (SDR28C2), hydroxybutyrate dehydrogenase BDH (SDR9C1), 17𝛽-HSD2 (SDR9C2), 11𝛽-HSD2
(SDR9C3), 3𝛼-HSD (SDR9C4), 11-cis retinol dehydrogenase (SDR9C5), 17𝛽-HSD6 (SDR9C6), retinol dehydrogenase SDR-O (SDR9C7),
and retinol dehydrogenase RDH16 (SDR9C8) in the lower panel. The locations of 𝛽-strand A through 𝛽-strand B are indicated above the
alignment. The position of the conserved Cys10 on 17𝛽-HSD1 is indicated by an arrow and the conserved glycine residues of the Rossmann-
fold by asterisks (in bold).
tetra-His antibody. Longer incubations with cycloheximide
were inappropriate due to toxic effects in HEK-293 cells.
Alternatively, cells transfected with plasmids for mutant
and wild-type enzyme were washed once 16 h after trans-
fection, followed by incubation in leucine-free DMEM (MP
Biomedicals, Illkirch, France) for 45min to deplete endoge-
nous leucine. The medium was then replaced by 1mL
of leucine-free DMEM supplemented with 20𝜇Ci/mL L-
leucine-[3,4,5-3H(N)], followed by incubation for 3 h. The
labeling was terminated by addition of 5mM unlabeled
leucine, washing twice with DMEM, and incubation in
DMEM. At 0, 12, 24, and 48 h, aliquots of cells were snap-
frozen prior to purification of histidine-tagged proteins by
using a Ni-NTA agarose kit according to the manufacturer
(Qiagen AG, Hombrechtikon, Switzerland). After elution,
proteins were subjected to SDS-PAGE, the gels were dried
and exposed to tritium-sensitive screens (TR uncoated
BaFBr:Eu2+ screens) for 16 h, followed by analysis using a
Cyclone Phosphor-Imager (PerkinElmer Life and Analytical
Sciences, Shelton, CT, USA).
2.5. Multiple Sequence Alignment. The protein sequences
of 17𝛽-HSD1 from different species and different human
SDRs were compared using the ClustalW algorithm, run on
http://www.ebi.ac.uk/, with default program parameters.
2.6. Structural Modeling. To investigate the effect on the
structure of 17𝛽-HSD1 of mutating Cys10 to Ser, we extracted
1FDT from the Protein Data Bank (PDB). 1FDT contains
human 17𝛽-HSD1 cocrystalized with estradiol and NADP+
[22]. Cys10 was converted to serine using the Biopolymer
option in the Insight II software package. The structure of
the Ser10 mutant 17𝛽-HSD1 was refined with Discover 3
for 10,000 iterations, using a distant dependent dielectric
constant of 2.
3. Results
3.1. Multiple Sequence Alignments and 3D Structure Modeling.
The analysis of the peptide sequence of human 17𝛽-HSD1
using the Clustal W algorithm [23] revealed that residue
Cys10 is highly conserved among species, including rodents
and zebrafish (Figure 1), suggesting a role for this residue in
the stability and/or function of the protein. Cys10 is located
between the first two of three highly conserved glycine
residues of the Rossmann-fold nucleotide binding domain.
Interestingly, the cysteine and the two downstream serine
residues also are present in all-trans retinol dehydrogenase
RDH8, which like 17𝛽-HSD1 belongs to the SDR28C family.
Moreover, the cysteine residue at this position is conserved
in all members of the SDR9C family, except for 17𝛽-HSD2,
which has a cysteine residue downstream by two positions.
To begin to understand the role of Cys10 for 17𝛽-HSD1
function, we analyzed the interactions of Cys10 with adjacent
amino acids in 17𝛽-HSD1 cocrystalized with estradiol and
NADP+ [22].The crystal structure of 1FDT reveals that Cys10
has van der Waals contacts with Ile7, Gly9, Gly15, Ala34, and
Thr35. Gly9, Gly15, and Thr35 directly stabilize the binding
of the cofactor NADP+ (Figure 2(a)). The numerous close
contacts of Cys10 with amino acids in the NADP(H)-binding
site indicate that substitution of the sulfhydryl group with
a larger chemical would disrupt this site and probably alter
NADP(H) binding and catalytic activity.
To begin to study the function of this cysteine residue, we
substituted Cys10 with serine, the biochemically most similar
amino acid. As revealed by the 3D model (Figure 2(b)),
mutating Cys10 to serine does not lead to significant changes
in contacts between Ser10 and Ile7, Gly9 and Ala34. However,
all three contacts between Ser10 and Gly15 are shorter than
between Cys10 and Gly15, and Gly15 is more distant from a
phosphate oxygen on NADP+ (Figure 2(b)). Also, Ser10 is a
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Figure 2: Position of Cys10 in wild-type 17𝛽-HSD1 and of Ser10 in
mutant 17𝛽-HSD1. Cys10 has stabilizing interactions with neighbor-
ing residues involved directly in the binding of cofactor NADPH.
A, wild-type 17𝛽-HSD1. Cys10 has van der Waals contacts with Ile7,
Gly9, Gly15, Ala34, andThr35. Gly9, Gly15, andThr35 contact NADP+.
B, Cys10Sermutant 17𝛽-HSD1. Ser10 has van derWaals contacts with
Ile7, Gly9, Gly15, Ala34, and Thr35. The backbone nitrogen on Gly9
and the backbone oxygen onThr35 no longer contact the oxygen on
the adenosine phosphate.
little more distant from the backbone oxygen on Thr35, and
Thr35 is 4.7> from the oxygen on the adenosine phosphate.
The backbone nitrogen on Gly9 is 4.5> from the same
phosphate oxygen on NADP+ (Figure 2(b)).
3.2. Inhibition of 17𝛽-HSD1 by Sulfhydryl Modifying Agents.
In a previous study, sulfhydryl modifying chemicals were
found to exert potent inhibitory effects on 11𝛽-HSD2 and
substitution of Cys90 by serine abolished enzymatic activ-
ity [20]. To test the hypothesis that Cys10 on 17𝛽-HSD1
has similar essential stabilizing interactions in the NADPH
binding region, we assessed the inhibitory potential of the
cysteine modifying agent N-ethylmaleimide (NEM) and of
dithiocarbamate chemicals. NEM appeared to be a weak
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Figure 3: Preincubation with NADPH protects 17𝛽-HSD1 from
inhibition by NEM. Lysates of HEK-293 cells expressing 17𝛽-HSD1
were preincubated for 15min with saline or various concentra-
tions of NADPH as indicated, prior to the addition of estrone
(200 nM), NADPH (400 𝜇M), and the sulfhydryl modifying agent
N-ethylmaleimide (NEM, 60 𝜇M). The estradiol produced was
determined after 10min of incubation. Data (mean ± SD) were
normalized to the control in the absence of NEM and were obtained
from at least three independent experiments measured in triplicate.
inhibitor with an IC
50
of 22 ± 6 𝜇M upon simultaneous
incubation of lysates of 17𝛽-HSD1 expressing HEK-293 cells
with 200 nM estrone and increasing concentrations of NEM.
In line with an irreversible mode of inhibition, preincubation
with NEM resulted in a more pronounced inhibitory effect
in a time-dependent manner. Preincubation of lysates with
20𝜇MNEMfor 1 h prior to the addition of estrone completely
abolished 17𝛽-HSD1 activity (data not shown).
Next, we tested dithiocarbamate chemicals for inhibition
of 17𝛽-HSD1. In contrast to the previously observed potent
inhibition of 11𝛽-HSD2, dithiocarbamates turned out to have
rather modest inhibitory effects on 17𝛽-HSD1. The IC
50
values for thiram (21 ± 4 𝜇M), disulfiram (8 ± 1 𝜇M), maneb
(25 ± 3 𝜇M), and zineb (24 ± 3 𝜇M) upon simultaneous incu-
bation of the 17𝛽-HSD1 enzyme preparation with substrate
and inhibitor were about two orders of magnitude higher
than those obtained for 11𝛽-HSD2, indicating that 17𝛽-HSD1
is much less prone to inhibition by sulfhydryl modification.
Importantly, as shown in Figure 3, preincubation with
NADPH for 15min protected from inhibition by NEM, an
effect which was concentration dependent. Preincubation
with NADPH also protected from inhibition by dithiocarba-
mates (data not shown), suggesting that binding of NADPH
prevents the covalent modification of Cys10 in the cofactor
binding region.
3.3. Substitution of Cys10 with Serine Leads to Decreased
Protein Stability. To study the role of Cys10 for 17𝛽-HSD1
function, we generated mutant Cys10Ser and compared
the expression of histidine-tagged wild-type and mutant
enzymes upon transient expression in HEK-293 cells, which
lack endogenous 17𝛽-HSD1 expression. Despite comparable
International Journal of Cell Biology 5
𝛽-Actin
17𝛽-HSD137 kDa
WT C10S
Figure 4: Western blot analysis of the protein expression of
histidine-tagged wild-type 17𝛽-HSD1 andmutant Cys10Ser. A repre-
sentative experiment from four independent transfections is shown.
transfection efficiency, mutant Cys10Ser was expressed at
approximately twofold lower levels than wild-type 17𝛽-HSD1
(Figure 4). Moreover, several low-molecular weight bands
were detected, indicating a lower stability of the Cys10Ser
mutant protein.
Next, we performed experiments in transfected HEK-
293 cells using cycloheximide in order to block de novo
protein synthesis and estimate protein half-life. The signal
detected for histidine-tagged 17𝛽-HSD1 protein was not
significantly decreased 48 h after blocking translation with
cycloheximide (Figure 5(a)), indicating a protein half-life
greater than 48 h. Longer incubations are not appropriate
due to the cytotoxicity of cycloheximide. In contrast, mutant
Cys10Ser was less stable and the protein half-life of themutant
enzyme was estimated to be 26 ± 7 h (mean ± SD). A pulse-
chase experiment using 3H-leucine labeling confirmed the
decreased stability of the mutant protein (estimated protein
half-life of 15 ± 6 h) compared with the wild-type 17𝛽-
HSD1 (estimated protein half-life of 36 ± 10 h) (Figure 5(b)).
The differences in the protein half-life estimation by the
pulse-chase and cycloheximide methods may be explained
by the incomplete inhibition of protein synthesis in the latter
approach.
3.4. Mutant Cys10Ser Retains Catalytic Activity and Is Pro-
tected from Inhibition by Sulfhydryl Modifying Agents. A
comparison of the enzyme activities of lysates expressing
wild-type 17𝛽-HSD1 or mutant Cys10Ser showed approxi-
mately 50% lower activity for the mutant (data not shown).
However, after correction for protein expression using anti-
histidine-tag antibody there was no significant difference
between wild-type and mutant enzymes. The analysis of
enzyme kinetics revealed a slightly higher apparent𝐾
𝑚
but no
significant change in the maximal velocity (𝑉max) for estrone
reduction (Table 1). In intact cells, the activity of mutant
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Figure 5: Stability of 17𝛽-HSD1 and Cys10Ser mutant. C-terminal
histidine-tagged wild-type 17𝛽-HSD1 and Cys10Sermutant enzymes
were expressed in HEK-293 cells. A, 24 h posttransfection cells were
incubated with 50𝜇g/mL cycloheximide to inhibit de novo protein
synthesis. After 0, 12, 24, and 48 h cells were harvested and the
amount of expressed protein was analyzed semiquantitatively using
anti-histidine antibody. 𝛽-actin served as control. B, the protein
half-life of 17𝛽-HSD1 and Cys10Ser mutant was estimated by pulse-
chase experiments, labeling cellular proteinswith tritiated L-leucine,
followed by washing and incubation in leucine-free medium for
different times. After purification of histidine-tagged proteins by
Ni-NTA agarose, proteins were separated by SDS-PAGE and gels
were dried and exposed to tritium-sensitive screens for detection of
radioactivity by phosphor-imaging. Representative experiments are
shown.
Table 1: Enzyme kinetics of wild-type 17𝛽-HSD1 and Cys10Ser
mutant. The reduction of various concentrations of estrone (10 to
800 nM) to estradiol was measured in cell lysates from transfected
HEK-293 cells in the presence of 400𝜇M NADPH. The data were
normalized according to protein expression and represent mean ±
SD from four independent experiments measured in triplicate.
𝑉max (nmol × h
−1 ×mg−1) 𝐾
𝑚
(nM)
17𝛽-HSD1 WT 110 ± 5 43 ± 6
17𝛽-HSD1 Cys10Ser 124 ± 3 65 ± 3
Cys10Ser was indistinguishable from that of the wild-type
enzyme (data not shown).
Next, we compared the effect of different dithiocarbamate
chemicals on the activity of wild-type 17𝛽-HSD1 and mutant
Cys10Ser. Mutant Cys10Ser was protected from inhibition by
all of the dithiocarbamates tested (Figure 6). Similarly, the
cysteine-modifying agent NEM inhibited the activity of the
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Figure 6: Inhibition of 17𝛽-HSD1 andCys10Sermutant by dithiocar-
bamate chemicals. The conversion of estrone (200 nM) to estradiol
in the presence of 400𝜇M NADPH and various dithiocarbamates
(80𝜇M final concentration) was measured in lysates of transfected
HEK-293 cells. Black bars, wild-type 17𝛽-HSD1 enzyme (WT); white
bars, Cys10Sermutant 17𝛽-HSD1 (C10S).The amount of total protein
in the reactionwas equalized to exclude differences due to unspecific
binding of the inhibitors to cellular proteins.
wild-type enzyme approximately two times stronger than that
of mutant Cys10Ser, confirming the role of this cysteine for
17𝛽-HSD1 function (data not shown).
4. Discussion
Analysis of the 17𝛽-HSD1 protein sequences from different
species revealed that the cysteine at position 10 in the human
enzyme is highly conserved. Protein sequence alignment fur-
ther revealed that a cysteine at this position in the Rossmann-
fold nucleotide binding region is conserved in the SDR
subfamilies SDR28C and SDR9C. The 3D structure of 17𝛽-
HSD1 predicts several van der Waals contacts between Cys10
and residues involved directly in the binding of NADPH.The
3Dmodel of Ser10mutant 17𝛽-HSD1 finds that althoughmost
contacts are conserved there are changes that may be signifi-
cant. For example, Ser10 is closer to Gly15, and Gly15 is more
distant from a phosphate oxygen on NADP+. Also, in the
Ser10 mutant 17𝛽-HSD1, the backbone oxygen on Thr35 and
backbone nitrogen on Gly9 move to 4.7> and 4.5>, respec-
tively, from the oxygen on the adenosine phosphate. In wild-
type 17𝛽-HSD1, the backbone oxygen onThr35 and backbone
nitrogen on Gly9 are 3.3> and 3.8>, respectively, from this
oxygen on NADP+. The loss of these two stabilizing contacts
could reduce the affinity for NADP(H) in the Ser10 mutant
17𝛽-HSD1. Another possible contribution to lower stability of
NADP(H) in the Ser10 mutant may be the different chemical
properties of the thiol group on Cys10 and alcohol on Ser10.
For instance, only the thiol group is predicted to be partially
deprotonated at neutral pH, which could better stabilize the
site around Cys10. 𝐾
𝑚
values for NADPH will need to be
determined in follow-on studies to address this question.
Nevertheless, our prediction is supported by results from
Huang et al. who demonstrated that insertion of a positively
charged lysine residue in the neighborhood of Cys10 and
Ser12 led to a more than 20-fold increase in the preference of
17𝛽-HSD1 for NADP(H) against NAD(H) [24]. In a previous
study, we found that the related SDR enzyme 11𝛽-HSD2 also
contains a cysteine residue at the position corresponding
to Cys10 on 17𝛽-HSD1 in the cofactor binding region [20].
The 11𝛽-HSD2 Cys90Ser mutant almost completely lost its
enzymatic activity, due to impaired protein folding and
mislocalization of the mutant protein.
Interestingly, mutations of the analogous residue Cys69
in the human (R)-3-hydroxybutyrate dehydrogenase led to
a slight increase in the apparent 𝐾
𝑚
for both NADP(H)
and NAD(H) [25]. The Cys69Ser mutant of the (R)-3-
hydroxybutyrate dehydrogenase, analogous to 17𝛽-HSD1
Cys10Ser, showed a twofold lower apparent 𝑉max compared
with thewild-type enzyme.The slight increase in the apparent
𝐾
𝑚
of 17𝛽-HSD1mutantCys10Ser for estrone, observed in our
measurements in cell lysates, indicates a decreased affinity for
the substrate as a result of disturbed interactions with the
cofactor NADPH. A careful structural comparison between
the interactions of residues with the cofactor and substrate in
17𝛽-HSD1, 11𝛽-HSD2, and (R)-3-hydroxybutyrate dehydro-
genase should offer an explanation for the different effects
of the modification of the analogous cysteine residues of the
three SDRs. In human retinol dehydrogenase, the function
of the analogous Cys38 is not studied in detail; however,
Boerman and Napoli showed that the protein contains cys-
teine residues in close proximity, which are essential for the
catalytic activity [26].
In our experiments, the preincubation with increasing
concentrations of NADPH was able to protect 17𝛽-HSD1
from inhibition by the sulfhydryl modifying agents NEM
and dithiocarbamates, suggesting an indirect role of Cys10 in
stabilizing the binding of the cofactor.
Dithiocarbamates and NEM were able to inhibit the
activity of 17𝛽-HSD1, although at concentrations significantly
higher than those needed for inhibition of 11𝛽-HSD2. The
high sensitivity of 11𝛽-HSD2 toward sulfhydryl modifying
chemicals was recently shown to be dependent on the
presence of a cysteine residue in the substrate binding region
[27]. An analogous cysteine residue is absent in the substrate
binding region of 17𝛽-HSD1. Our western blot experiments
detected low-molecular bands for the 17𝛽-HSD1 Cys10Ser
mutant, suggesting increased degradation of the mutant
enzyme. The more rapid degradation is likely due to changes
in the protein conformation and thus exposure of amino
acid residues normally buried inside the protein, followed
by activation of the proteasome. A limitation of the present
study includes that wild-type andmutant enzymes were over-
expressed and expression levels are higher than endogenous
levels. Thus, the estimated half-life of the proteins may be
different in an endogenous situation. Nevertheless, the results
demonstrate a reduced stability of the mutant compared with
the wild-type enzyme.
International Journal of Cell Biology 7
The present work provides novel information on the
structure-activity relationship of 17𝛽-HSD1 and reveals that
Cys10 is involved in essential stabilizing interactions in the
cofactor binding region. Furthermore, we showed that Cys10
is the target for sulfhydryl modifying agents. Future studies
using protease digestion of purified 17𝛽-HSD1 wild-type and
Cys10Sermutant proteins should provide furthermechanistic
insight into the stabilizing interactions of this residue.
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